Lodestar Investment Counsel LLC IL reduced its stake in Johnson & Johnson (NYSE:JNJ) by 1.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 216,944 shares of the company’s stock after selling 2,895 shares during the period. Johnson & Johnson makes up about 3.7% of Lodestar Investment Counsel LLC IL’s investment portfolio, making the stock its 2nd biggest holding. Lodestar Investment Counsel LLC IL’s holdings in Johnson & Johnson were worth $28,699,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Lenox Wealth Advisors Inc. increased its holdings in Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its holdings in Johnson & Johnson by 241.0% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after purchasing an additional 841 shares in the last quarter. Ullmann Financial Group Inc. acquired a new stake in Johnson & Johnson in the 1st quarter valued at $186,000. Taylor Wealth Management Partners increased its holdings in Johnson & Johnson by 19.8% in the 1st quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock valued at $188,000 after purchasing an additional 250 shares in the last quarter. Finally, Puplava Financial Services Inc. acquired a new stake in Johnson & Johnson in the 2nd quarter valued at $202,000. Hedge funds and other institutional investors own 65.90% of the company’s stock.

In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the transaction, the vice president now directly owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the transaction, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by company insiders.

JNJ has been the subject of several recent research reports. Royal Bank Of Canada reiterated a “buy” rating and issued a $128.00 price target on shares of Johnson & Johnson in a report on Thursday, June 15th. Jefferies Group LLC reiterated a “hold” rating and issued a $140.00 price target on shares of Johnson & Johnson in a report on Friday, June 16th. BidaskClub upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Wednesday, July 5th. Finally, Wells Fargo & Company reissued a “market perform” rating and issued a $135.00 price objective (up from $132.00) on shares of Johnson & Johnson in a research report on Thursday, July 6th. Five equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $135.98.

ILLEGAL ACTIVITY NOTICE: This report was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/10/13/johnson-johnson-jnj-is-lodestar-investment-counsel-llc-ils-2nd-largest-position.html.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The business had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. During the same period last year, the firm earned $1.74 earnings per share. Johnson & Johnson’s revenue for the quarter was up 1.9% compared to the same quarter last year.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.